Enhabit (EHAB) Scheduled to Post Quarterly Earnings on Tuesday

Enhabit (NYSE:EHAB) will release its earnings data after the market closes on Tuesday, August 6th. Analysts expect Enhabit to post earnings of $0.05 per share for the quarter. Enhabit has set its FY 2024 guidance at 0.120-0.430 EPS.Parties interested in participating in the company’s conference call can do so using this link.

Enhabit (NYSE:EHAB) last released its earnings results on Wednesday, May 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. The company had revenue of $262.40 million during the quarter, compared to the consensus estimate of $268.25 million. Enhabit had a negative net margin of 7.95% and a positive return on equity of 1.43%. On average, analysts expect Enhabit to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Enhabit Trading Down 3.8 %

Shares of NYSE EHAB opened at $9.67 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.50 and a current ratio of 1.50. The stock has a market cap of $485.05 million, a price-to-earnings ratio of -5.83, a PEG ratio of 1.58 and a beta of 1.85. The business has a 50 day simple moving average of $9.20 and a 200 day simple moving average of $9.70. Enhabit has a 52 week low of $7.12 and a 52 week high of $14.22.

Insiders Place Their Bets

In other news, Director Jeffrey Bolton purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The shares were acquired at an average cost of $8.33 per share, with a total value of $83,300.00. Following the purchase, the director now owns 52,299 shares in the company, valued at $435,650.67. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders acquired 22,000 shares of company stock worth $183,700. Company insiders own 1.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Leerink Partnrs upgraded shares of Enhabit from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 14th. Jefferies Financial Group downgraded shares of Enhabit from a “buy” rating to a “hold” rating and reduced their price target for the stock from $14.00 to $8.75 in a research report on Thursday, May 9th. SVB Leerink upgraded shares of Enhabit from an “underperform” rating to a “market perform” rating and set a $8.50 target price on the stock in a research report on Tuesday, May 14th. Finally, Bank of America decreased their price objective on Enhabit from $9.00 to $8.00 and set an “underperform” rating for the company in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $9.79.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.